Frankfurt - Delayed Quote EUR

Ironwood Pharmaceuticals, Inc. (I76.F)

0.5750

-0.0350

(-5.74%)

At close: April 15 at 7:08:01 PM GMT+2

Ironwood Shares Tank on Regulatory Update for Apraglutide

Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.

Zacks 11 hours ago

IRWD
Ironwood’s shares sink as FDA demands new trial for lead drug

The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.

Pharmaceutical Technology 13 hours ago

IRWD

GLDAF
Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks advanced late Monday afternoon with the NYSE Health Care Index gaining 1.4% and t

PREMIUM
MT Newswires yesterday

IRWD
Top Midday Decliners

Ironwood Pharmaceuticals (IRWD) said Monday that a confirmatory phase 3 trial is needed to seek appr

PREMIUM
MT Newswires yesterday

IRWD

HOLOW
Sector Update: Health Care Stocks Rise Monday Afternoon

Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the

PREMIUM
MT Newswires yesterday

IRWD

AMGN

PFE
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

BOSTON, April 14, 2025--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral support.

Business Wire yesterday

IRWD
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday?

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at where Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) stands against other stocks that fall behind amid market optimism. Wall Street’s main indices rebounded from hefty losses on Wednesday after President Donald Trump announced that […]

Insider Monkey 5 days ago

IRWD

^GSPC
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 14 days ago

CORT

IRWD
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

BOSTON, March 27, 2025--Ironwood Pharmaceuticals, Inc. (the "Company") (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that it received a notification letter (the "Notice") on March 21, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for

Business Wire 19 days ago

IRWD
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?

Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 21 days ago

CPRX

IRWD
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now?

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) stands against the other small cap pharma stocks. Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry Emily Field, Head of […]

Insider Monkey last month

IRWD

ABBV
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down

Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.

Zacks last month

IRWD

ABBV
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ...

Ironwood Pharmaceuticals Inc (IRWD) reports robust LINZESS demand growth and strategic focus on apraglutide, while navigating pricing headwinds and debt management.

GuruFocus.com last month

IRWD
Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call

Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

IRWD
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -80% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

IRWD
Ironwood: Q4 Earnings Snapshot

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 10 cents per share. The drugmaker posted revenue of $90.5 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $92 million.

Associated Press Finance last month

IRWD
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

BOSTON, February 27, 2025--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results and recent business performance.

Business Wire last month

IRWD
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

BOSTON, February 20, 2025--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood’s

Business Wire last month

IRWD
Millrose Properties Set to Join S&P SmallCap 600

Millrose Properties Inc. (NYSE: MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE: LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. Following the spin-off, Lennar will remain in the S&P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&P Sma

PR Newswire 2 months ago

IRWD

LEN

LEN-B
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls

Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.

Zacks 2 months ago

IRWD

ABBV

Performance Overview

Return	I76.F	S&P 500 (^GSPC)
YTD	-86.24%	-8.25%
1-Year	-92.18%	+6.61%
3-Year	-94.93%	+22.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ironwood Pharmaceuticals, Inc. (I76.F)

Ironwood Shares Tank on Regulatory Update for Apraglutide

Ironwood’s shares sink as FDA demands new trial for lead drug

Sector Update: Health Care Stocks Rise Late Afternoon

Top Midday Decliners

Sector Update: Health Care Stocks Rise Monday Afternoon

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday?

Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?

Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now?

IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down

Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ...

Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call

Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates

Ironwood: Q4 Earnings Snapshot

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Millrose Properties Set to Join S&P SmallCap 600

IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls

Performance Overview